Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김지은 | * |
dc.contributor.author | 류인균 | * |
dc.contributor.author | 윤수정 | * |
dc.date.accessioned | 2016-08-28T10:08:42Z | - |
dc.date.available | 2016-08-28T10:08:42Z | - |
dc.date.issued | 2012 | * |
dc.identifier.issn | 0002-953X | * |
dc.identifier.other | OAK-9163 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222970 | - |
dc.description.abstract | Objective: Antidepressants targeting mono-aminergic neurotransmitter systems, despite their immediate effects at the synaptic level, usually require several weeks of administration to achieve clinical efficacy. The authors propose a strategy of adding creatine monohydrate (creatine) to a selective serotonin reuptake inhibitor (SSRI) in the treatment of patients with major depressive disorder. Such augmentation may lead to a more rapid onset of antidepressant effects and a greater treatment response, potentially by restoring brain bioenergetics at the cellular level. Method: Fifty-two women with major depressive disorder were enrolled in an 8-week double-blind placebo-controlled clinical trial and randomly assigned to receive escitalopram in addition to either creatine (5 g/day, N=25) or placebo (N=27). Efficacy was primarily assessed by changes in the Hamilton Depression Rating Scale (HAM-D) score. Results: In comparison to the placebo augmentation group, patients receiving creatine augmentation showed significantly greater improvements in HAM-D score, as early as week 2 of treatment. This differential improvement favoring creatine was maintained at weeks 4 and 8. There were no differences between treatment groups in the proportion of patients who discontinued treatment prematurely (creatine: N=8, 32.0%; placebo: N=5, 18.5%) or in the overall frequency of all reported adverse events (creatine: 36 events; placebo: 45 events). Conclusions: The current study suggests that creatine augmentation of SSRI treatment may be a promising therapeutic approach that exhibits more rapid and efficacious responses in women with major depressive disorder. | * |
dc.language | English | * |
dc.title | A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder | * |
dc.type | Article | * |
dc.relation.issue | 9 | * |
dc.relation.volume | 169 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SSCI | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 937 | * |
dc.relation.lastpage | 945 | * |
dc.relation.journaltitle | American Journal of Psychiatry | * |
dc.identifier.doi | 10.1176/appi.ajp.2012.12010009 | * |
dc.identifier.wosid | WOS:000308278100010 | * |
dc.identifier.scopusid | 2-s2.0-84865838010 | * |
dc.author.google | Lyoo I.K. | * |
dc.author.google | Yoon S. | * |
dc.author.google | Kim T.-S. | * |
dc.author.google | Hwang J. | * |
dc.author.google | Kim J.E. | * |
dc.author.google | Won W. | * |
dc.author.google | Bae S. | * |
dc.author.google | Renshaw P.F. | * |
dc.contributor.scopusid | 김지은(55353332200) | * |
dc.contributor.scopusid | 류인균(55664289900) | * |
dc.contributor.scopusid | 윤수정(15766754400) | * |
dc.date.modifydate | 20240220114752 | * |